Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment

Open access
Davidson, Sophia, McCabe, Teresa M, Crotta, Stefania, Gad, Hans Henrik, Hessel, Edith M, Beinke, Soren, Hartmann, Rune, Wack, Andreas·2016·EMBO Molecular Medicine

Abstract

Influenza A virus ( IAV )‐induced severe disease is characterized by infected lung epithelia, robust inflammatory responses and acute lung injury. Since type I interferon ( IFN αβ) and type III interferon ( IFN λ) are potent antiviral cytokines with immunomodulatory potential, we assessed their efficacy as IAV treatments. IFN λ treatment of IAV ‐infected Mx1‐positive mice lowered viral load and protected from disease. IFN α treatment also restricted IAV replication but exacerbated disease. IFN α treatment increased pulmonary proinflammatory cytokine secretion, innate cell recruitment and epithelial cell death, unlike IFN λ‐treatment. IFN λ lacked the direct stimulatory activity of IFN α on immune cells. In epithelia, both IFN s induced antiviral genes but no inflammatory cytokines. Similarly, human airway epithelia responded to both IFN α and IFN λ by induction of antiviral genes but not of cytokines, while hPBMC s responded only to IFN α. The restriction of both IFN λ responsiveness and productive IAV replication to pulmonary epithelia allows IFN λ to limit IAV spread through antiviral gene induction in relevant cells without overstimulating the immune system and driving immunopathology. We propose IFN λ as a non‐inflammatory and hence superior treatment option for human IAV infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.15252/emmm.201606413

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 240

Metadata

Authors
Davidson, S., McCabe, T. M., Crotta, S., Gad, H. H., Hessel, E. M., Beinke, S., Hartmann, R., & Wack, A.
Venue
EMBO Molecular Medicine
Published
2016-08-12
Volume
8
Issue
9
Pages
1099-1112
ISSN
  • 1757-4676 (ISSN-L)
  • 1757-4684
OpenAlex
W2517547699
Cited by
240
References
4
FWCI
8.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment. https://app.cochat.ai/papers/10.15252/emmm.201606413
The paper
Davidson, S., McCabe, T. M., Crotta, S., Gad, H. H., Hessel, E. M., Beinke, S., Hartmann, R., & Wack, A. (2016). IFN λ is a potent anti‐influenza therapeutic without the inflammatory side effects of IFN α treatment. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.201606413

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.